In a nutshell The current study examined the risk of developing acute myeloid leukemia/myelodysplastic syndrome (tAML/MDS) following treatment for Hodgkin lymphoma. The study determined that there was an association between alkylating agent chemotherapy and the risk of tAML/MDS. Some background Treatments for Hodgkin lymphoma have been associated...
Read More
In a nutshell The current article reviewed the treatment options for nodular lymphocyte predominant Hodgkin lymphoma. The article highlighted standard treatment options as well as the experience of one medical center. Some background Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an uncommon type of Hodgkin lymphoma. It occurs in...
Read MoreIn a nutshell This study examined the long-term risk of cardiovascular disease (CVD, heart and blood vessel disease) in treated Hodgkin lymphoma patients. The authors concluded that the risk of CVD was higher in Hodgkin lymphoma survivors compared to the general population. The average time between treatment and CVD was 19 years. Some background...
Read More
In a nutshell This study summarized guidelines for the role of stem cell transplantation in patients with Hodgkin lymphoma. Some background While Hodgkin lymphoma is a curable disease in many, some patients experience a disease relapse or they do not respond to treatment. These patients are often treated with further chemotherapy followed by a...
Read More
In a nutshell The current study explored the long-term risk of second cancers following chemotherapy for Hodgkin lymphoma. This study concluded that while there is an increased risk it is lower than the risk with combined chemotherapy and radiation. Some background New treatments for Hodgkin lymphoma have resulted in it being a curable disease....
Read More
In a nutshell This review discussed factors that help to determine prognosis (outcome) in Hodgkin lymphoma. Some background Hodgkin lymphoma is generally considered to be a curable form of cancer. However, it is important to have methods to predict outcomes in order to avoid either over-treating or under-treating patients. The current article...
Read More
In a nutshell The current study examined the use of VEPEMB chemotherapy in Hodgkin lymphoma patients 60 years or older. This study determined that VEPEMB was safe and effective in in older patients with few other health problems. This study also demonstrated that patients who saw a complete remission with VEPEMB (no sign of cancer) were more likely to...
Read MoreIn a nutshell This study compared three chemotherapy combinations, standard dose BEACOPP, increased dose BEACOPP, and COPP-ABVD, for advanced Hodgkin lymphoma. The authors concluded that increased-dose BEACOPP was more effective. Some background The standard chemotherapies for advanced Hodgkin lymphoma (stage III or IV or those with additional...
Read MoreIn a nutshell This article summarized some of the possible late effects of Hodgkin lymphoma treatment. Some background The standard treatment options for Hodgkin lymphoma are radiation and chemotherapy. These treatments have led to very high remission rates (no sign of disease) in many patients. Radiation and chemotherapy have also been associated...
Read More
In a nutshell This study examined the safety and effectiveness of the chemotherapy ESHAP in Hodgkin lymphoma that had relapsed (returned), or that had not responded to treatment. This study concluded that ESHAP was safe and effective in these patients. Some background Hodgkin lymphoma is often curable. Some patients do not respond to treatment, or...
Read More
In a nutshell This study examined the safety and effectiveness of the Stanford V chemotherapy combination in patients with early-stage Hodgkin lymphoma. The authors concluded that Stanford V was effective in the long-term in these patients. Some background Early-stage Hodgkin lymphoma (stages I-II) is considered to be a curable disease. Treatment...
Read MoreIn a nutshell This study examined the safety and effectiveness of the chemotherapy combination IGEV. This study concluded that this combination benefitted patients with Hodgkin lymphoma who had relapsed or who had not responded to other treatment. Some background Recent treatments for Hodgkin lymphoma have led to very high cure rates. Some...
Read More
